Shen N, Zhang L, Yang J, Lin Y, Liu X, Cai X, Cao J, Zhu Q, Luo X, Wan X, Wu H, Ye J, Shan C, Xie H, Wu Y, Cao Y, Wang J, Yu X, Wang H, He J, Tian S, Wu F, Jiang X, Li L, Zuo L, Wang Z, Xing C, Yin X, Zhao J, Ma C, Long G, Li Q, Hu Y, Shi Y, and Lin H
Introduction: Sodium zirconium cyclosilicate (SZC) is a nonabsorbed cation-exchanger approved in China for the treatment of hyperkalemia [HK; serum potassium (sK + ) levels >5.0 mmol/L]. This is the first real-world study aimed to assess the effectiveness, safety, and treatment patterns of SZC in Chinese patients with HK. Here we present the results of the first interim analysis. Methods: This multicenter, prospective, cohort study included patients aged ≥18 years with documented HK within 1-year before study enrollment day. These patients were followed up for 6 months from the enrollment day after initiating SZC treatment. The treatment was categorized into correction phase (FAS-P1) and maintenance phase (FAS-P2 new and ongoing users). Subgroup analysis was performed in patients on hemodialysis (FAS-H). The primary objective was evaluation of safety profile of SZC; secondary objectives included assessment of treatment patterns of SZC and its effectiveness. Results: Of 421 screened patients, 193, 354, and 162 patients were enrolled in the FAS-P1, FAS-P2, and FAS-H groups, respectively. sK + levels were reduced significantly from 5.9 mmol/L to 5.0 mmol/L after the correction phase. For the maintenance phase, the mean sK + levels were maintained at 5.2 mmol/L and 5.0 mmol/L in the FAS-P2 new and ongoing user, respectively, and 5.3 mmol/L in the FAS-H subgroup. A considerable proportion of patients showed normokalemia after 48 h of SZC treatment (FAS-P1:51.3%) which was maintained up to 6 months in the maintenance phase (FAS-P2:44%). SZC was well-tolerated. Conclusion: SZC was effective and safe for the treatment of HK in real-world clinical practice in China., Competing Interests: Author YS was employed by AstraZeneca Investment China Co. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from AstraZeneca Investment China. The funder was involved in the study design, but was not involved in the collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., (Copyright © 2024 Shen, Zhang, Yang, Lin, Liu, Cai, Cao, Zhu, Luo, Wan, Wu, Ye, Shan, Xie, Wu, Cao, Wang, Yu, Wang, He, Tian, Wu, Jiang, Li, Zuo, Wang, Xing, Yin, Zhao, Ma, Long, Li, Hu, Shi and Lin.)